Innovent Biologics, Inc.

IVBXF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$95-$1,144-$2,170-$2,729
Dep. & Amort.$420$385$319$205
Deferred Tax$0$0$0$50
Stock-Based Comp.$557$574$469$502
Change in WC$450$403$310-$90
Other Non-Cash-$44-$70-$847$37
Operating Cash Flow$1,287$148-$1,919-$2,025
Investing Activities
PP&E Inv.$0-$1,119-$1,382-$1,848
Net Acquisitions$0$0$0-$630
Inv. Purchases$0-$9,414-$10,326-$10,338
Inv. Sales/Matur.$0$9,244$10,020$10,121
Other Inv. Act.-$1,165$291$252-$4
Investing Cash Flow-$1,165-$999-$1,435-$2,698
Financing Activities
Debt Repay.-$730$418$715$1,208
Stock Issued$84$2,255$2,131$3,951
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$39-$86$46-$155
Financing Cash Flow-$607$2,587$2,892$5,003
Forex Effect$13-$7$119-$197
Net Chg. in Cash-$472$1,730-$343$83
Supplemental Information
Beg. Cash$2,746$1,016$1,359$1,276
End Cash$2,273$2,746$1,016$1,359
Free Cash Flow-$418-$1,236-$3,301-$3,872